Van Hulzen Asset Management, LLC Vertex Pharmaceuticals Inc Transaction History

Van Hulzen Asset Management, LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 Apr 28, 2023	SELL	$283.23 - $323.1 $154,926 - $176,735	-547 Reduced 9.58%	5,163 $1.63 Million
Q4 2022 Feb 13, 2023	SELL	$285.76 - $321.48 $1,143 - $1,285	-4 Reduced 0.07%	5,710 $1.65 Million
Q3 2022 Nov 08, 2022	BUY	$273.83 - $305.53 $3,833 - $4,277	14 Added 0.25%	5,714 $1.65 Million
Q2 2022 Aug 04, 2022	SELL	$234.96 - $292.55 $16.8 Million - $20.9 Million	-71,600 Reduced 92.63%	5,700 $1.61 Million
Q1 2022 May 20, 2022	BUY	$221.42 - $260.97 $1.64 Million - $1.93 Million	7,399 Added 10.58%	77,300 $20.2 Million
Q4 2021 Feb 04, 2022	BUY	$177.01 - $223.45 $12.4 Million - $15.6 Million	69,901 New	69,901 $15.4 Million

1,726

221M

1.58M

1.36M

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $105B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

Get notified when there are updates to the investment portfolio of Van Hulzen Asset Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Van Hulzen Asset Management, LLC with notifications on news.